Aspen Neuroscience (NASDAQ:ASPE) Stock: Insider Venture Fund L.P. Arch Acquires 133,333 Shares

Aspen Neuroscience, Inc. (NASDAQ:ASPE) major shareholder Venture Fund L.P. Arch acquired 133,333 shares of Aspen Neuroscience stock in a transaction dated Monday, November 2nd. The stock was acquired at an average cost of $15.00 per share, with a total value of $1,999,995.00. Following the completion of the transaction, the insider directly owned 66,667 shares of the company’s stock, valued at $1,000,005. This trade represents a -200.00% increase in their position. The acquisition was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Major shareholders that own 10% or more of a company’s shares are required to disclose their sales and purchases with the SEC.

Aspen Neuroscience Stock Up 3.8%

Shares of ASPE stock opened at $12.76 on Thursday. Aspen Neuroscience, Inc. has a 1 year low of $11.20 and a 1 year high of $14.90.

About Aspen Neuroscience

Aspen Neuroscience, Inc is a biotechnology company focused on developing regenerative medicine therapies for neurological disorders. The company’s approach uses a patient’s own cells to create induced pluripotent stem cells, which are then differentiated into specialized cells intended to replace damaged or lost tissue.

Aspen’s lead program, ANPD001, is designed as a potential cell replacement therapy for Parkinson’s disease. The company has also developed genetic screening and manufacturing processes intended to evaluate a patient’s cells and produce an individualized therapeutic product.

Aspen Neuroscience is headquartered in San Diego, California.